[Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone].
Pardo López
M A
MA
Cuadrado Pastor
J M
JM
Pérez Hervás
M P
MP
Fernández Villalba
E
E
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects*; D004338:Drug Combinations; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000209:etiology; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects*; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D008691:Methadone; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D000099227:Abacavir; C418262:abacavir, lamivudine, and zidovudine drug combination